RxDoctor Payments Data

William Kim, MD

Internal Medicine · Torrance, CANPI 1457302499

Payments from drug & device makers

$669in general payments, 2019–2025

Across 29 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$107
  • AstraZeneca$98
  • Stryker$81
  • Boston Scientific$76
  • Amgen$64
  • AbbVie$56
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$669 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$241,837
Medicare patients
443
Services billed
3,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$130,074
FarxigaDapagliflozin Propanediol55$67,352
XareltoRivaroxaban46$44,970
XifaxanRifaximin12$38,507
MyrbetriqMirabegron34$26,175
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$22,299
MounjaroTirzepatide20$20,723
JanuviaSitagliptin Phosphate18$18,824
OzempicSemaglutide11$17,856
Repatha SureclickEvolocumab20$17,287
EntrestoSacubitril/Valsartan17$11,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,959
Atorvastatin Calcium458$4,883
Quetiapine Fumarate28$2,996
SynthroidLevothyroxine Sodium51$2,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$130,074115 claims
AstraZenecaFarxiga, Breztri Aerosphere$98$89,65282 claims
Johnson & JohnsonXarelto$107$44,97046 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$38,50712 claims
Lilly USA, LLCMounjaro$20$20,72320 claims
AbbVieSynthroid, Armour Thyroid$56$4,65573 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →